Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library
Drug companies and transparency of clinical trial data | Dr. David Healy
Humira, INN - adalimumab
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet
تويتر \ Dr T ² | 🙈 🙉 🙊 على تويتر: "Found this gem while going through old records: denial of Humira for #Crohns because it was deemed experimental. Forced me into
Taking Citrate-Free Humira: What Patients Need to Know
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet
BioSpace Feature: A Look at Miracle Drug Humira's Journey to Proven Efficacy | BioSpace
First clinical trial with D2E7 (Humira) - YouTube
Adalimumab - Wikipedia
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Annals of the Rheumatic Diseases
Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review
Frontiers | Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial | Medicine
Adalimumab: a review of the reference product and biosimilars | BS
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
AbbVie Move Against Data Transparency | Reuters Events | Pharma
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Humira Biosimilars Clinical Trial Insight - Research and Markets
PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram
HUMIRA (adalimumab) Dermatology Healthcare Professional Site